Fig. 2
From: An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant
Determination of EC50 and IC50 by ELISA. A ELISA-based WT SARS-CoV-2 S1 (fusion protein with His tag) binding assay of Bi-Nab. B ELISA binding assay of Bi-Nab to mutated SARS-CoV-2 S1 (fusion protein with a His tag). The EC50, the concentration for 50% of the maximal effect, is used as a parameter for assessing the affinity between antibodies and spike proteins. C ELISA analysis of Bi-Nab or parental mAbs or cocktail-mediated inhibition of WT RBD protein (fusion protein with mouse Fc part) binding to human ACE2. The IC50, the half-maximal inhibitory concentration, was determined by sigmoidal dose‒response nonlinear regression. D The ELISA statistics of Bi-Nab, a cocktail, and parental mAbs are shown in the tables